Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Allan Jaffe MD

Allan S. Jaffe MD

Professor of Medicine, Professor of Laboratory Medicine and Pathology, and Wayne and Kathryn Presiel Professor of Cardiovascular Disease Research, Mayo Clinic, Rochester, Minnesota

Dr. Allan Jaffe is a graduate of the University of Maryland School of Medicine. He received his house staff and Cardiology training at Washington University and continued there for 22 years rising to the rank of Professor of Medicine and Director of the Coronary Care Unit. He then moved to the State University of New York where he was Chair of the Cardiovascular Division, Associate Chair of Medicine for Academic Affairs, and Professor of Medicine. After four years he moved to the Mayo Clinic where he is presently Professor of Medicine in the Cardiovascular Division and Professor and Chair of the Division of Core Clinical Laboratory Services in the Department of Laboratory Medicine and Pathology. He is a noted authority on biomarkers of cardiac injury, inflammation, hemodynamic disturbance, and coagulation and particularly their clinical utility. He has published a large number of original manuscripts, book chapters, reviews, and sits on most of the prestigious editorial boards and guideline committees in the Cardiology and Clinical Chemistry communities.

Disclosure:  Dr. Jaffe has, or presently consults for most of the major diagnostic companies.

Disclosures

Dr. Jaffe has or presently consults for most of the major diagnostic companies, including the ones responsible for the assay results in the paper being reviewed (see below).

Direct Comparison of Four Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I
Circulation 3/10/2017;[EPub Ahead of Print], Jasper Boeddinghaus, Thomas Nestelberger, Raphael Twerenbold, Karin Wildi, Patrick Badertscher, Janosch Cupa, Tobias Bürge, Patrick Mächler

Recent Contributions to PracticeUpdate:

  1. hs-cTnI Concentrations for Risk Assessment in Patients With Chronic CAD
  2. Influence of Age on the Diagnosis of Myocardial Infarction
  3. Rapid Exclusion of Acute Myocardial Injury and Infarction With a Single hs-cTnT in the Emergency Department
  4. High-Sensitivity Troponin I After Cardiac Surgery and 30-Day Mortality
  5. Novel Criteria for the Observe-Zone of the ESC 0/1h hs-cTnT Algorithm
  6. Diagnostic Performance of hs-cTn Strategies and Clinical Variables in a Multisite US Cohort
  7. Cardiac Procedural Myocardial Injury, Infarction, and Mortality in Patients Undergoing Elective PCI
  8. Cardiovascular Mortality After Type 1 and Type 2 Myocardial Infarction in Young Adults
  9. Type 2 Myocardial Infarction
  10. Cardiac Troponin Elevation in Patients Without a Specific Diagnosis

Most Read This Week

Recently Updated